Ocular toxicity of hydroxychloroquine

Seminars in Ophthalmology

Volumn 23, Issue 3, 2008, Pages 201-209

  Tehrani, Rodney ^a   Ostrowski, Rochella A ^a   Hariman, Richard ^a   Jay, Walter M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chloroquine; Hydroxychloroquine; Plaquenil; Retinopathy

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE;

BLURRED VISION; CLINICAL FEATURE; COLOR VISION; DIAGNOSTIC ACCURACY; DRUG SCREENING; DRUG WITHDRAWAL; ELECTRORETINOGRAM; EYE EXAMINATION; EYE TOXICITY; FLUORESCENCE ANGIOGRAPHY; HUMAN; LIGHT; LOW DRUG DOSE; METAMORPHOSIS; PRIORITY JOURNAL; RETINOPATHY; REVIEW; RHEUMATIC DISEASE; SKIN DISEASE; VISUAL DISORDER; VISUAL FIELD DEFECT;

ANTIMALARIALS; ANTIRHEUMATIC AGENTS; ELECTRORETINOGRAPHY; FLUORESCEIN ANGIOGRAPHY; HUMANS; HYDROXYCHLOROQUINE; INCIDENCE; RETINAL DISEASES; RISK FACTORS; VISUAL FIELDS;

EID: 42449150064     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530802049962     Document Type: Review

References (49)

1. Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet 1959; 2:478-480.
2. Shearer RV, Dubois EL. Ocular changes induced by long term hydroxychloroquine (Plaquenil) therapy. AM J Ophthalmol 1967; 64:245-252.
3. Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis & Rheumatism 1997 Aug;40(8):1482-6.
4. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatologic Therapy 2007; 20(4):160-174.
5. Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001 Sep 8;358(9284):813-4.
6. Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Medical Journal. 2006 Aug;12(4):294-304.
7. Jones SK. Ocular toxicity and hydroxychloroquine: Guidelines for screening. Br J Dermatol. 1999 Jan;140(1):3-7.
8. Easterbrook M. The ocular safety of hydroxychloroquine. Seminars in Arthritis & Rheumatism. 1993 Oct;23(2 Suppl 1):62-7.
9. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol. 1991;23:292-6.
10. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: A report by the american academy of ophthalmology. Ophthalmology. 2002 Jul;109(7):1377-82.
11. Lai TY, Chan WM, Li H, Lai RY, Lam DS. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol. 2005 Nov;140(5):794-807.
12. Rodriguez-Padilla JA, Hedges TR, 3rd, Monson B, Srinivasan V, Wojtkowski M, Reichel E, et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol. 2007 Jun;125(6):775-80.
13. Elder M, Rahman AM, McLay J. Early paracentral visual field loss in patients taking hydroxychloroquine. Arch Ophthalmol. 2006 Dec;124(12):1729-33.
14. Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis. 1997 Mar;56(3):188-90.
15. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol. 1987 Aug 15;104(2):139-44.
16. Thorne JE, Maguire AM. Retinopathy after long term, standard doses of hydroxychloroquine. British Journal of Ophthalmology. 1999;83:1201-1202.
17. Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas K. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis. 1996 Mar;55(3):187-9.
18. Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: A reappraisal. Ophthalmology. 2003; 110:1321-1326.
19. Lyons JS, Severns ML. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol. 2007 May;143(5):801-9.
20. Maturi RK, Yu M, Weleber RG. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol. 2004 Jul;122(7):973-81.
21. Falcone PM, Paolini L, Lou PL. Hydroxychloroquine toxicity despite normal dose therapy. Ann Ophthalmol. 1993 Oct;25(10):385-8.
22. Shroyer NF, Lewis RA, Lupski JR. Analysis of the ABCR(ABCA4) gene in 4-aminoquinoline retinopathy. American Journal of Opthalmology. 2001; 131:761-766.
23. American Academy of Ophthalmology. Preferred practice pattern.
24. Easterbrook M. Detection and prevention of maculopathy associated with antimalarial agents. Int Ophthalmol Clin. 1999;39:49-57.
25. Bienfang DC. Screening for hydroxychloroquine toxicity. Arch Ophthalmol 2007 author reply 1585; Nov; 125(11):1585.
26. Almony A, Garg S, Peters RK, Mamet R, Tsong J, Shibuya B, et al. Threshold amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy. Br J Ophthalmol. 2005 May;89(5):569-74.
27. Razeghinejad MR, Torkaman F, Amini H. Blue-yellow perimetry can be an early detector of hydroxychloroquine and chloroquine retinopathy. Med Hypotheses. 2005;65(3):629-30.
28. Bienfang D, Coblyn JS, Liang MH, Corzillius M. Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: A consecutive series. J Rheumatol. 2000;27:2703-6.
29. Gilbert ME, Savino PJ. Missing the bull's eye. Surv Ophthalmol. 2007 Jul-Aug;52(4):440-2.
30. Marmor MF. The dilemma of hydroxychloroquine screening: New information from the multifocal ERG. Am J Ophthalmol. 2005 Nov;140(5):894-5.
31. Teoh SC, Lim J, Koh A, Lim T, Fu E. Abnormalities on the multifocal electroretinogram may precede clinical signs of hydroxychloroquine retino-toxicity. Eye. 2006 Jan;20(1):129-32.
32. Mavrikakis I, Mavrikakis E. Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance. comment on the article by samanta et al. Rheumatology. 2004 author reply 1059; Aug;43(8):1057-8.
33. Sanofi-Aventis. Plaquenil: Prescribing Information Including Black Box Warning. Sanofi-Aventis. 2006.
34. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum. 1996;39:723-31.
35. Block JA. Hydroxychloroquine and retinal safety. Lancet. 1998 Mar 14;351(9105):771.
36. Blyth C, Lane C. Hydroxychloroquine retinopathy: Is screening necessary?[ see comment]. BMJ. 1998 Mar 7;316(7133):716-7.
37. Spalton DJ. Retinopathy and antimalarial drugs - The British experience. Lupus. 1996 Jun;5(Suppl 1):S70-2.
38. Royal College of Ophthalmology. Ocular Toxicity and Hydroxychloroquine: Guidelines for Screening. 2004.
39. Silman A, Shipley M. Ophthalmologic monitoring for hydroxychloroquine toxicity: A scientific review of available data. Pr J Rheumatol. 1997;36(5):599-601.
40. Coyle JT. Hydroxychloroquine retinopathy. Ophthalmology. 2001 Feb;108(2):243-4.
41. Lee AG. Hydroxychloroquine screening. Br J Ophthalmol. 2005 May;89(5):521-2.
42. Alarcon GS. How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy? Arthritis & Rheumatism. 2002 Feb; 46(2):561.
43. Easterbrook M. Hydroxychloroquine retinopathy. Ophthalmology. 2001 Dec;108(12):2158-9.
44. Cimaz R, Brucato A, Meregalli E, Muscara M, Sergi P. Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: Comment on the article by Costedoat-Chalumeau et al. Arthritis & Rheumatism. 2004 author reply 3057-8; Sep;50(9):3056-7.
45. Motta M, Tincani A, Faden D, Zinzini E, Chirico G. Antimalarial agents in pregnancy. Lancet. 2002 Feb 9;359(9305):524-5.
46. Wei LC, Chen SN, Ho CL, Kuo YH, Ho JD. Progression of hydroxychloroquine retinopathy after discontinuation of therapy: Case report. Chang Gung Med J. 2001 May;24(5):329-34.
47. Brinkley JR, Jr, Dubois EL, Ryan SJ. Long-term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol. 1979 Jul;88(1):1-11.
48. Raines MF, Bhargava SK, Rosen ES. The blood-retinal barrier in chloroquine retinopathy. Invest Ophthalmol Vis Sci. 1989 Aug;30(8):1726-31.
49. Reed H, Karlinsky W. Delyed onset of chloroquine retinopathy. Can Med Assoc J. 1967;97:1408-11.